UNIVERSITY OF MIAMI STUDY
The University of Miami tested the ability of BioLexa’s DTPA chelator to synergize with the antibiotic in an animal study. Specifically, the pre-clinical study introduced high levels of Staph bacteria to wounds on the skin of pigs, as pig skin is the closet animal model to human skin. The results, as set forth in this chart, show significant reduction in bacterial infection. In some cases, the bacterial count was below detectable levels.
Link to Study: https://hoththerapeutics.com/wp-content/uploads/2018/01/Miami-Study.pdf
MASSACHUSETTS GENERAL HOSPITAL – DIABETIC FOOT ULCER PILOT STUDY
This pilot study was designed to establish foundational protocols for assessing effectiveness of a therapeutic compound developed by Hoth Therapeutics, the BioLexa Platform, for accelerating and improving wound healing in the context of acute and chronic diabetic ulcers, using an animal model of impaired wound healing developed at Massachusetts General Hospital (MGH).
MINIPIG PHASE I IN-LIFE DOSE ESCALTION STUDY
MINIPIG GLP 28-DAY REPEAT DOSE TOXICITY
BOVINE CORNEAL OPACITY AND PERMEABILITY TEST
BEUHLER SENSITIZATION STUDY
PROPOSED FUTURE STUDIES:
FRANZ CELL ASSAY – IN VITRO PERCUTANEOUS ABSORPTION STUDY
CLINICAL TRIAL IN HUMANS
INVESTOR RELATIONS
Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.